Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Healthcare Triangle Q2 FY26 gross profit more than doubled to $2.07 million; revenue more than doubled to $9.19 million

Healthcare Triangle Q2 FY26 gross profit more than doubled to $2.07 million; revenue more than doubled to $9.19 million

ReutersReuters2026/08/13 12:15
  • Healthcare Triangle posted Q2 revenue of $9.19 million, more than doubled from a year earlier.
  • Gross profit rose to $2.07 million; gross margin widened 8.7 percentage points to 22.5%.
  • AI-powered customer engagement segment generated $6.31 million, about 69% of quarterly revenue.
  • First-half revenue reached $19.05 million; gross profit climbed to $4.46 million.
  • Stockholders’ equity increased to $49.1 million at June 30, from $9.9 million at Dec. 31.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Healthcare Triangle Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130815PR_NEWS_USPR_____SF25644) on August 13, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well